Compare Abbott India with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs GLENMARK PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA GLENMARK PHARMA ABBOTT INDIA/
GLENMARK PHARMA
 
P/E (TTM) x 47.0 10.6 445.0% View Chart
P/BV x 13.5 1.5 891.6% View Chart
Dividend Yield % 0.5 0.7 76.9%  

Financials

 ABBOTT INDIA   GLENMARK PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
GLENMARK PHARMA
Mar-19
ABBOTT INDIA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110712 858.6%   
Low Rs3,996484 826.3%   
Sales per share (Unadj.) Rs1,552.2349.6 444.0%  
Earnings per share (Unadj.) Rs188.832.8 576.0%  
Cash flow per share (Unadj.) Rs196.444.3 443.1%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.3 325.2%  
Book value per share (Unadj.) Rs796.6198.6 401.0%  
Shares outstanding (eoy) m21.25282.17 7.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.7 190.5%   
Avg P/E ratio x26.818.2 146.8%  
P/CF ratio (eoy) x25.713.5 190.8%  
Price / Book Value ratio x6.33.0 210.9%  
Dividend payout %29.16.1 477.5%   
Avg Mkt Cap Rs m107,376168,625 63.7%   
No. of employees `0003.312.0 27.6%   
Total wages/salary Rs m3,93720,561 19.1%   
Avg. sales/employee Rs Th9,929.38,196.0 121.1%   
Avg. wages/employee Rs Th1,185.11,708.1 69.4%   
Avg. net profit/employee Rs Th1,207.7768.5 157.2%   
INCOME DATA
Net Sales Rs m32,98598,655 33.4%  
Other income Rs m1,1702,081 56.2%   
Total revenues Rs m34,155100,736 33.9%   
Gross profit Rs m5,24515,858 33.1%  
Depreciation Rs m1623,259 5.0%   
Interest Rs m383,346 1.1%   
Profit before tax Rs m6,21511,335 54.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m2,2033,756 58.6%   
Profit after tax Rs m4,0129,250 43.4%  
Gross profit margin %15.916.1 98.9%  
Effective tax rate %35.433.1 106.9%   
Net profit margin %12.29.4 129.7%  
BALANCE SHEET DATA
Current assets Rs m22,65566,968 33.8%   
Current liabilities Rs m6,68140,211 16.6%   
Net working cap to sales %48.427.1 178.6%  
Current ratio x3.41.7 203.6%  
Inventory Days Days6583 77.7%  
Debtors Days Days2981 35.9%  
Net fixed assets Rs m83533,322 2.5%   
Share capital Rs m213282 75.3%   
"Free" reserves Rs m16,71555,770 30.0%   
Net worth Rs m16,92856,052 30.2%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m24,162132,888 18.2%  
Interest coverage x163.74.4 3,730.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.40.7 183.9%   
Return on assets %16.89.5 176.9%  
Return on equity %23.716.5 143.6%  
Return on capital %36.917.8 207.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36962,998 0.6%   
Fx outflow Rs m3,80722,859 16.7%   
Net fx Rs m-3,43840,140 -8.6%   
CASH FLOW
From Operations Rs m1,52713,242 11.5%  
From Investments Rs m-2,148-6,990 30.7%  
From Financial Activity Rs m-1,024-7,387 13.9%  
Net Cashflow Rs m-1,646-2,971 55.4%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 6.9 114.5%  
FIIs % 0.1 34.4 0.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 10.5 162.9%  
Shareholders   18,270 56,727 32.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  VENUS REMEDIES  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - AJANTA PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS